Manulife

FACT SHEET

MANULIFE DANA EKUITAS TEKNOLOGI KESEHATAN GLOBAL DOLAR

AUG 2026

Investment Objective

To achieve long term capital growth by investing mainly in equity securities of companies which predominant economic activities are in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology sectors, onshore and/or offshore, directly and/or through mutual fund(s).

Risk Classification

Risk classification is based on type of fund.



Fund Information

Inception Date	:	18 Oct 21
Inception Price	:	USD 1.0000
Fund Size	:	USD 522,880.63
Number of unit	:	427,355.00
Net Asset Value/Unit [3]	:	USD 1.2235
Fund Currency	:	USD
Type of fund	:	Equity
Valuation	:	Daily
Custodian Bank	:	Bank DBS Indonesia
Annual Management Fee	:	2.50%
Bloomberg Code	:	MATKGMU IJ
Fund Manager	:	PT Manulife Aset Manajemen Indonesia

Allocation

Equity	:	80 - 100 %
Money Market	:	0 - 20 %

Portfolio

Equity	:	98.95%
Money Market	:	1.05%

Note

1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
2) The benchmark is MSCI World Healthcare Net Total Return USD Index.
3) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Performance Since Inception



Monthly Performance Last 3 Years



Fund Performance

Performance in USD per (31/08/26)

	1 mo	3 mo	6 mo	YTD	1 yr	3 yr [1]	5 yr [1]	Since Inception [1]
MANTKG	3.96%	8.97%	2.50%	4.46%	16.12%	6.39%	n/a	4.23%
BM [2]	3.71%	10.47%	3.01%	6.68%	19.65%	8.41%	n/a	5.81%

Yearly Performance

	2025	2024	2023	2022	2021	2020	2019	2018
MANTKG	12.68%	2.19%	1.17%	-4.60%	n/a	n/a	n/a	n/a
BM [2]	15.55%	0.94%	3.76%	-5.68%	n/a	n/a	n/a	n/a

Top Holdings* & Sector Allocation

Mutual Fund - BlackRock Global Funds - World Healthscience Fund



Non Affiliates

Investment Manager Commentary

Global healthcare stocks delivered positive performance in August 2026, as investors diversify toward earnings-resilient businesses amid ongoing uncertainty over inflation, Fed policy, and geopolitics. Global market sentiment was driven by healthy 2Q corporate earnings. Markets, however, remained cautious amid expectations that the Federal Reserve could keep interest rates higher for longer, following hawkish comments from Fed Chair Kevin Warsh. Meanwhile geopolitical tensions in the Middle East and elevated oil prices sustained inflation concerns that drove global yields to rise. This environment favored sectors with dependable cash flows and less economic sensitivity, including healthcare. Healthcare valuations remained at a discount to the broader market despite favorable long-term fundamentals, supporting renewed investor interest. Pharmaceutical and biotechnology companies led performance, aided by strong demand trends and continued innovation in key therapeutic areas, while medical devices and life sciences tools lagged. Overall, we remain constructive on the sector, supported by favorable long-term trends including aging populations, healthcare innovation, and advances in biotechnology and medical technology.

Manulife Indonesia

Established in 1985, PT Asuransi Jiwa Manulife Indonesia (Manulife Indonesia) is part of Manulife Financial Corporation Group, a Canadian financial services group that operates in Asia, Canada and the United States. Manulife Indonesia offers a wide range of financial services, including life insurance, accident and health insurance, investment and pension plans to individual customers and group clients in Indonesia. Through a network of almost 11,000 employees and professional agents spread across more than 30 sales offices, Manulife Indonesia serves around 2 million customers in Indonesia.
PT Asuransi Jiwa Manulife Indonesia are licensed and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit www.manulife.co.id.